85 related articles for article (PubMed ID: 19289368)
1. Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy.
Herbst RS; Lynch TJ; Sandler AB
Clin Lung Cancer; 2009 Jan; 10(1):20-7. PubMed ID: 19289368
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
3. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
Langer F; Helsberg K; Schütte WH; Leschinger MI
Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.
Di Maio M; Chiodini P; Georgoulias V; Hatzidaki D; Takeda K; Wachters FM; Gebbia V; Smit EF; Morabito A; Gallo C; Perrone F; Gridelli C
J Clin Oncol; 2009 Apr; 27(11):1836-43. PubMed ID: 19273711
[TBL] [Abstract][Full Text] [Related]
6. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.
Hotta K; Fujiwara Y; Matsuo K; Suzuki T; Kiura K; Tabata M; Takigawa N; Ueoka H; Tanimoto M
Cancer; 2007 Mar; 109(5):939-48. PubMed ID: 17285602
[TBL] [Abstract][Full Text] [Related]
7. [Comparison between single-agent and platinum-doublet chemotherapy in elderly patients with non-small cell lung cancer].
Tamiya A; Naito T; Takahashi T; Endo M; Yamamoto N
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1897-901. PubMed ID: 20948252
[TBL] [Abstract][Full Text] [Related]
8. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
Grossi F; Aita M; Follador A; Defferrari C; Brianti A; Sinaccio G; Belvedere O
Oncologist; 2007 Apr; 12(4):451-64. PubMed ID: 17470688
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer.
Raez LE; Kobina S; Santos ES
Clin Lung Cancer; 2010 Jan; 11(1):18-24. PubMed ID: 20085863
[TBL] [Abstract][Full Text] [Related]
10. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.
D'Addario G; Pintilie M; Leighl NB; Feld R; Cerny T; Shepherd FA
J Clin Oncol; 2005 May; 23(13):2926-36. PubMed ID: 15728229
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
12. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.
Gridelli C; Aapro M; Ardizzoni A; Balducci L; De Marinis F; Kelly K; Le Chevalier T; Manegold C; Perrone F; Rosell R; Shepherd F; De Petris L; Di Maio M; Langer C
J Clin Oncol; 2005 May; 23(13):3125-37. PubMed ID: 15860872
[TBL] [Abstract][Full Text] [Related]
14. Optimizing first-line treatment options for patients with advanced NSCLC.
Wakelee H; Belani CP
Oncologist; 2005; 10 Suppl 3():1-10. PubMed ID: 16368866
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
[TBL] [Abstract][Full Text] [Related]
16. Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: current status and future challenges.
Pallis AG; Syrigos K
Cancer Treat Rev; 2012 Nov; 38(7):861-7. PubMed ID: 22217701
[TBL] [Abstract][Full Text] [Related]
17. Advances in chemotherapy of non-small cell lung cancer.
Molina JR; Adjei AA; Jett JR
Chest; 2006 Oct; 130(4):1211-9. PubMed ID: 17035458
[TBL] [Abstract][Full Text] [Related]
18. Implications of key trials in advanced nonsmall cell lung cancer.
Bonomi PD
Cancer; 2010 Mar; 116(5):1155-64. PubMed ID: 20087963
[TBL] [Abstract][Full Text] [Related]
19. Second-line therapy for non-small-cell lung cancer.
Arango BA; Castrellon AB; Santos ES; Raez LE
Clin Lung Cancer; 2009 Mar; 10(2):91-8. PubMed ID: 19362951
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer.
Johnson ML; Patel JD
Semin Oncol; 2014 Feb; 41(1):93-100. PubMed ID: 24565583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
